Yahoo Finance AbCellera Biologics First Quarter 2023 Earnings: EPS Misses Expectations
AbCellera Biologics (NASDAQ:ABCL) First Quarter 2023 Results
Key Financial Results
Revenue: US$12.2m (down 96% from 1Q 2022).
Net loss: US$40.1m (down by 124% from US$168.6m profit in 1Q 2022).
US$0.14 loss per share (down from US$0.59 profit in 1Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
AbCellera Biologics EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 11%.
Looking ahead, revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's shares are down 12% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with AbCellera Biologics, and understanding it should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
